Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo
Researchers in the Democratic Republic of Congo have launched a clinical trial for Gilead Sciences' experimental antiviral drug, obeldesivir, to treat the Bundibugyo Ebola outbreak. The study is supported by international medical organizations in the Ituri province.
Why it matters
Testing new antiviral treatments in active outbreak zones is critical for developing effective responses to future Ebola epidemics.
July 14 (Reuters) – Researchers in the Democratic Republic of Congo said on Tuesday they have started enrolling participants in a trial testing Gilead Sciences’ GILD.O experimental antiviral obeldesivir as a post-exposure treatment for the ongoing Bundibugyo Ebola outbreak in Congo and Uganda.
The article is a straightforward report on a medical trial based on a Reuters wire release.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in